Romlusevimab

Names

[ Name ]:
Romlusevimab

Biological Activity

[Description]:

Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][2].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> SARS-CoV

[In Vitro]

Romlusevimab 和 Amubarvimab (HY-P99435) 结合 SARS-CoV-2 刺突蛋白的不同表位[1]。 Romlusevimab 与 Amubarvimab 联合使用时具有累加效应[1] 。

[In Vivo]

Romlusevimab (10 mg/kg，ip，单次)与 Amubarvimab (HY-P99435) 联合使用可在 SARS-CoV-2 感染小鼠模型中保护动物免受 Omicron 感染[1]。

[References]

[1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331.

[2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.